Insider Selling: Guardant Health (NASDAQ:GH) Insider Sells 10,031 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 10,031 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $112.08, for a total value of $1,124,274.48. Following the sale, the insider directly owned 20,990 shares in the company, valued at approximately $2,352,559.20. The trade was a 32.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Guardant Health Stock Performance

GH stock traded up $1.43 during trading on Friday, hitting $110.17. The stock had a trading volume of 2,411,196 shares, compared to its average volume of 2,552,194. Guardant Health, Inc. has a 1-year low of $34.80 and a 1-year high of $113.91. The company’s 50 day moving average price is $101.80 and its two-hundred day moving average price is $72.73. The stock has a market cap of $13.89 billion, a price-to-earnings ratio of -34.32 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same period last year, the company earned ($0.88) earnings per share. The business’s revenue was up 38.5% on a year-over-year basis. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

GH has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Wednesday, October 8th. Mizuho set a $135.00 price target on shares of Guardant Health in a research report on Friday. JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Guggenheim lifted their price target on shares of Guardant Health from $85.00 to $115.00 and gave the company a “buy” rating in a report on Monday. Finally, Leerink Partners boosted their price objective on shares of Guardant Health from $115.00 to $155.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Twenty-two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.81.

Hedge Funds Weigh In On Guardant Health

A number of hedge funds have recently made changes to their positions in GH. AQR Capital Management LLC boosted its position in Guardant Health by 56.5% during the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after purchasing an additional 25,831 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Guardant Health by 6.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,236 shares of the company’s stock worth $3,035,000 after buying an additional 4,056 shares during the period. Empowered Funds LLC acquired a new stake in shares of Guardant Health in the first quarter valued at about $274,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Guardant Health by 6.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company’s stock valued at $118,302,000 after buying an additional 164,263 shares during the period. Finally, Intech Investment Management LLC raised its holdings in shares of Guardant Health by 37.3% during the 1st quarter. Intech Investment Management LLC now owns 60,187 shares of the company’s stock valued at $2,564,000 after buying an additional 16,363 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.